ONO-2020
Alzheimer’s Disease
Phase 2Active
Key Facts
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a commercial-stage oncology company with a core focus on developing novel kinase inhibitors using its proprietary switch-control platform. Its achievements include the 2020 FDA approval of QINLOCK for advanced GIST and the 2025 approval of ROMVIMZA for TGCT, solidifying its transition to a commercial entity. Following its 2024 acquisition by Japan's ONO Pharmaceutical, Deciphera now operates as a key U.S./European subsidiary, leveraging enhanced resources to advance a robust, diversified pipeline. The company's strategy centers on overcoming drug resistance in cancer and expanding into new therapeutic areas through internal R&D and strategic collaboration.
View full company profileTherapeutic Areas
Other Alzheimer’s Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| SPC-14 | Silo Pharma | Preclinical |
| Masitinib | AB Science | Phase 3 |
| Leronlimab | CytoDyn | Phase 1 |
| Alzheimer's Drug | Dawah Pharmaceuticals | Development |
| Alzheimer’s Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| Blarcamesine (ANAVEX®2-73) | Anavex Life Sciences | Phase 2b/3 |